The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-10. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Benefits == SASP can aid in signaling to immune cells for senescent cell clearance, with specific SASP factors secreted by senescent cells attracting and activating different components of both the innate and adaptive immune system. The SASP cytokine CCL2 (MCP1) recruits macrophages to remove cancer cells. Although transient expression of SASP can recruit immune system cells to eliminate cancer cells as well as senescent cells, chronic SASP promotes cancer. Senescent hematopoietic stem cells produce a SASP that induces an M1 polarization of macrophages which kills the senescent cells in a p53-dependent process. Autophagy is upregulated to promote survival. SASP factors can maintain senescent cells in their senescent state of growth arrest, thereby preventing cancerous transformation. Additionally, SASP secreted by cells that have become senescent because of stresses can induce senescence in adjoining cells subject to the same stresses, thereby reducing cancer risk. SASP can play a beneficial role by promoting wound healing. SASP may play a role in tissue regeneration by signaling for senescent cell clearance by immune cells, allowing progenitor cells to repopulate tissue. In development, SASP also may be used to signal for senescent cell clearance to aid tissue remodeling. The ability of SASP to clear senescent cells and regenerate damaged tissue declines with age. In contrast to the persistent character of SASP in the chronic inflammation of multiple age-related diseases, beneficial SASP in wound healing is transitory.
COVID-19 in the UK: Lockdown Files: The Telegraph publishes messages that are reported to have been exchanged between Allan Nixon, a parliamentary Advisor and Matt Hancock from November 2020 in which they discuss threatening to cancel projects in MPs' constituencies if MPs do not support the local lockdown tiers legislation. It is also reported that as part of a strategy aimed at trying to stop MPs from rebelling against the legislation, party whips compiled a spreadsheet of 95 MPs who disagreed with this policy and the reasons for them disagreeing; these related to lack of parliamentary scrutiny, economic harm, harms to hospital, absence of cost benefit analysis and the policy being "unconservative". 7 March A cold snap from the Arctic hits the UK, causing snowfall in Scotland and parts of northern England. Two coal fire power stations are also reactivated amid concerns about the strain the cold snap could cause on the National Grid. Home Secretary Suella Braverman introduces the Illegal Migration Bill into the House of Commons, which is designed to stop migrants arriving in the UK by boat. The legislation proposes to detain and remove those from the UK who arrive by illegal means, as well as blocking them from returning. COVID-19 in the UK: The Joint Committee on Vaccination and Immunisation announces that everyone over 75, care-home residents and anyone considered to be extremely vulnerable aged five and over will be offered a spring COVID-19 booster vaccine.
Also, alphaproteobacteria present a potentially large source of the lipid in the rock record. It has been suggested that these organisms may be synthesizing gammacerane in response to other shifting parameters during water column stratification, as most of the bacteria that contain the ths gene thrive in dynamic environments.
The operation of nuclear power plants and other nuclear facilities produces radioactive materials that can have lethal health effects for thousands of years. It is important to note that there is no institution capable of maintaining the necessary knowledge of the dangers over such periods, and of ensuring that warnings about the dangers of nuclear waste in nuclear repositories will be understood by posterity in the distant future. A few years ago, even the capsules of the radionuclide cobalt-60, which were appropriately labeled, went unnoticed. Improper disposal led to the opening of these capsules, resulting in fatal consequences. The dimensions of time exceed previous human standards. For instance, cuneiform writing, which is only about 5000 years old (about 150 human generations), can only be understood after a long period of research and by experts. In 1981, research into the development of atomic semiotics began in the USA, in the German-speaking world, Roland Posner (1942-2020) of the Center for Semiotics at Technische Universität Berlin worked on this in 1982/83. In the USA, the time horizon for such warning signs was set at 10,000 years; later, as in Germany, it was set at a period of one million years, which would correspond to about 30,000 (human) generations. To date, no satisfactory solution to this problem has been found.
Sources: en.wikipedia.org
==== Distribution ==== The plasma protein binding of atenolol is 6 to 16%. Atenolol is classified as a hydrophilic beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier and entering the brain. This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects. Only small amounts of atenolol are said to enter the brain. The brain-to-blood ratio of atenolol in humans has been found to be 0.2:1, whereas the ratio for the highly lipophilic propranolol has been found to range from 15:1 to 33:1.
== Further reading == Sitruk-Ware R, Bricaire C, De Lignieres B, Yaneva H, Mauvais-Jarvis P (October 1987). "Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications--a review". Contraception. 36 (4): 373–402. doi:10.1016/0010-7824(87)90088-6. PMID 3327648. Simon JA (December 1995). "Micronized progesterone: vaginal and oral uses". Clinical Obstetrics and Gynecology. 38 (4): 902–14. doi:10.1097/00003081-199538040-00024. PMID 8616985. Ruan X, Mueck AO (November 2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–55. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.
Teratogenic effects with therapeutic doses of suvorexant in humans have not been established due to lack of research and available data. Suvorexant is pregnancy category C in the United States. It is unknown whether suvorexant is present in the breast milk, whether it affects lactation in breastfeeding women, or whether it affects breastfed infants. However, suvorexant has been found to be present in mammary milk in rats and this is likely to be the case in humans as well. Suvorexant should be used in pregnant and breastfeeding women only if the potential benefit justifies the potential for harm to the baby.
Sources: en.wikipedia.org
==== Kessel Linares drops his claim ==== In September 2025, one week before the session regularly scheduled session of the semi-annual meeting of the High Chamber of the Grand Lodge of Cuba, Acting Grand Master Kessel Linares reiterated that the Director of the Office of Associations at the Ministry of Justice was still attempting to interfere with the proceedings and to keep Filema Duarte in power. Three days before the semi-annual meeting, Acting Grand Secretary Víctor Bravo resigned, and called for a boycott of the session, telling the members that the session would be pointless. On September 28, 2025, at the semi-annual meeting of the High Chamber, Acting Grand Master Kessel Linares announced that he had dropped his claim to the office of Grand Master, and proposed to dismiss the removal of Grand Master Filema Duarte. A minority of the Lodges present voted yea, but the vote did pass (indicating that a large portion abstained). After the vote, a large number of Freemasons were seen leaving the building with what appeared to be looks of disgust and outrage on their faces. Dozens of Freemasons interviewed by the press informed them that they felt betrayed once again, and believed that Kessel Linares had finally caved to the pressure being applied to him by the Ministry of Justice. One Freemason said: "Freemasonry in Cuba is over." Another said: "Kessel has betrayed his oath." One Cuban Freemason was quoted as saying: "The regime has had us infiltrated for decades, but now the agents have been brazenly exposed.
=== SOMC LIFE Center === The LIFE Center provides full service fitness and rehabilitation facilities in Scioto County through centers in Portsmouth, Wheelersburg and Lucasville. Additionally, SOMC has hosted events designed to promote fitness and physical activity, such as the ‘Tri For Your LIFE’ sprint triathlon and ‘Run for your LIFE’ 5/10k. In its first year, SOMC's ‘Tri For Your LIFE’ triathlon featured more than 100 competitors.
=== Translational repression === The translation initiation factor eIF4E is tightly regulated by the fragile X mental retardation protein (FMRP), which controls the translation of specific mRNAs at synapses. FMRP interacts with CYFIP1, which directly binds eIF4E at a domain structurally analogous to those found in canonical 4E-binding proteins such as EIF4EBP1, EIF4EBP2, and EIF4EBP3. This interaction competitively inhibits eIF4G binding, thereby blocking assembly of the eukaryotic translation initiation complex and repressing translation. The FMRP–CYFIP1–eIF4E complex is further stabilized by dendritically localized, non-coding RNAs such as BC1, which enhance FMRP-CYFIP1 interactions and mediate recruitment to specific target mRNAs. This repressive complex is responsive to neuronal stimulation. Synaptic activity promotes the dissociation of CYFIP1 from eIF4E, thereby allowing eIF4G to bind and initiate translation. This mechanism enables dynamic, activity-dependent regulation of protein synthesis at the synapse, contributing to processes such as synaptic plasticity and learning. Since eIF4E is an initiation factor that is relatively low in abundance, eIF4E can be controlled at multiple levels. Regulation of eIF4E may be achieved at the levels of transcription, RNA stability phosphorylation, subcellular localization and partner proteins.
ACS Applied Materials & Interfaces. 16 (12): 14633–14644. Bibcode:2024AAMI...1614633K. doi:10.1021/acsami.4c02243. PMC 10982941. PMID 38483312. Karki, Sandeep; Malhotra, Sahil; Ijaz, Muhammad; Rollet, Nicolas; O'Cearbhaill, Eoin D.; Bini, Estela; Brayden, David J. (2026). "A pullulan-based bilayer film for buccal delivery of a GLP-1 peptide analogue". Carbohydrate Polymers. 380 125064. doi:10.1016/j.carbpol.2026.125064. PMID 41831981.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.